Everus Construction Group, Inc. provides contracting services in the United States. It operates through two segments, Electrical & Mechanical and Transmission & Distribution. The Electrical & Mechanical segment provides construction and maintenance services of electrical and communication wiring, and infrastructure; fire suppression systems; and renewables infrastructure and mechanical piping services in public and private sectors. The Transmission & Distribution segment offers construction and maintenance of overhead and underground electrical, gas, and communication infrastructure and transportation related lighting, as well as design, manufacturing, and distribution of overhead and underground transmission line construction equipment and tools. It serves utilities, manufacturing, transportation, commercial, industrial, institutional, renewables, and governmental customers. The company was incorporated in 2024 and is headquartered in Bismarck, North Dakota. Everus Construction Group, Inc. was formerly a subsidiary of MDU Resources Group, Inc.…
Everus Announces Authorization of New $100 Million Share Repurchase Program
Everus Construction Group (NYSE: ECG) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Engineering & Construction industry, part of the Industrials sector, and reports about 9,400 employees.
The shares were at 76.59 USD on 20 November 2026, down 9.5% over 52 weeks. Its 52-week range is 70.44 USD to 171.58 USD: the price is 55.4% below the high and 8.7% above the low.
At a market capitalisation of 3.91B USD, it trades at 13.6 times trailing earnings and 10.8 times forward earnings. The median trailing P/E of its 19 largest Engineering & Construction peers is 23.6, a discount of 43% for ECG.
Everus Construction Group reports return on equity of 32.0%, an operating margin of 8.2% and revenue up 40.3% year over year.
Its debt exceeds its cash by 458.20M USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 146.83 USD is 91.7% above the current price. The next earnings report is expected on 23 February 2027.